Further studies to determine the accuracy of GUS in the setting of GLP-1 RAs would be beneficial to set guidelines for the preoperative use of GUS in the setting of GLP-1 RA, as well as clarifying uncertainty within these guidelines among these patients
Jansen T, Hortmann M, Oelze M, Opitz B, Steven S, Schell R, et al
GLP-1 Safety Disclaimer: GLP-1 receptor agonist medications carry documented safety information including risk of pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia (particularly in combination with insulin or sulfonylureas), serious hypersensitivity reactions, and - for FDA-approved tirzepatide and semaglutide products - a Boxed Warning regarding risk of thyroid C-cell tumors
Browse all Pip pen needle options For more general sizing context (including pen needles for traditional insulin pens), see Pip's existing Lancet & Pen Needle Size Guide and the Pen Needles & Insulin Syringes: Ultimate Guide
The honest breakdown: GLP-1 receptor agonists, yes, absolutely, with strong peer-reviewed data